Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Chronic Myeloproliferative Disorders

Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate

Abstract

Mutations of the BCR-ABL kinase domain are a common mechanism of resistance to imatinib in chronic myeloid leukemia. We screened for mutations 171 patients failing imatinib therapy. Sixty-six mutations in 23 amino acids were identified in 62 (36%) patients not responding to imatinib. Phosphate-binding loop (P-loop) mutations were the most frequent (n=24; 36%). By multivariate analysis, factors associated with development of mutations were older age (P=0.026) prior interferon therapy (P=0.026), and accelerated phase or blast phase at time of imatinib failure (P=0.001). After a median follow-up of 38 months (range, 4–68 months) from the start of imatinib therapy, seven patients with non-P-loop and two with P-loop mutation died. By multivariate analysis, development of clonal evolution and higher percentage of peripheral blood basophils were associated with worse survival from the time of imatinib failure. Mutation status had no impact on survival. When survival was measured from the time therapy started, non-P-loop mutations together with duration of response and transformation at the time of failure to imatinib were associated with shorter survival. In conclusion, P-loop mutations were not associated with poor outcome, suggesting that the prognosis of patients who fail imatinib is multifactorial.

This is a preview of subscription content

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

Figure 1
Figure 2

References

  1. Goldman JM, Melo JV . Chronic myeloid leukemia – advances in biology and new approaches to treatment. N Engl J Med 2003; 349: 1451–1464.

    CAS  Article  PubMed  Google Scholar 

  2. Cortes J, Talpaz M, O’Brien S, Jones D, Luthra R, Shan J et al. Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate. Clin Cancer Res 2005; 11: 3425–3432.

    CAS  Article  PubMed  Google Scholar 

  3. Hughes TP, Kaeda J, Branford S, Rudzki Z, Hochhaus A, Hensley ML et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 2003; 349: 1423–1432.

    CAS  Article  PubMed  Google Scholar 

  4. Hochhaus A, Kreil S, Corbin AS, La Rosee P, Muller MC, Lahaye T et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia 2002; 16: 2190–2196.

    CAS  Article  PubMed  Google Scholar 

  5. Gambacorti-Passerini CB, Gunby RH, Piazza R, Galietta A, Rostagno R, Scapozza L . Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias. Lancet Oncol 2003; 4: 75–85.

    Article  PubMed  Google Scholar 

  6. Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001; 293: 876–880.

    CAS  Article  PubMed  Google Scholar 

  7. Branford S, Rudzki Z, Walsh S, Parkinson I, Grigg A, Szer J et al. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood 2003; 102: 276–283.

    CAS  Article  PubMed  Google Scholar 

  8. Gambacorti-Passerini C, Zucchetti M, Russo D, Frapolli R, Verga M, Bungaro S et al. Alpha1 acid glycoprotein binds to imatinib (STI571) and substantially alters its pharmacokinetics in chronic myeloid leukemia patients. Clin Cancer Res 200; 9: 625–632.

    Google Scholar 

  9. Donato NJ, Wu JY, Stapley J, Lin H, Arlinghaus R, Aggarwal BB et al. Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia. Cancer Res 2004; 64: 672–677.

    CAS  Article  PubMed  Google Scholar 

  10. Donato NJ, Wu JY, Stapley J, Gallick G, Lin H, Arlinghaus R et al. BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood 2003; 101: 690–698.

    CAS  Article  PubMed  Google Scholar 

  11. Branford S, Rudzki Z, Walsh S, Grigg A, Arthur C, Taylor K et al. High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood 2002; 99: 3472–3475.

    CAS  Article  PubMed  Google Scholar 

  12. Soverini S, Martinelli G, Rosti G, Bassi S, Amabile M, Poerio A et al. ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA working party on chronic myeloid leukemia. J Clin Oncol 2005; 23: 4100–4109.

    CAS  Article  PubMed  Google Scholar 

  13. Nardi V, Azam M, Daley GQ . Mechanisms and implications of imatinib resistance mutations in BCR-ABL. Curr Opin Hematol 2004; 11: 35–43.

    CAS  Article  PubMed  Google Scholar 

  14. Corbin AS, Rosee PL, Stoffregen EP, Druker BJ, Deininger MW . Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib. Blood 2003; 101: 4611–4614.

    CAS  Article  PubMed  Google Scholar 

  15. Branford S, Rudzki Z, Parkinson I, Grigg A, Taylor K, Seymour JF et al. Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations. Blood 2004; 104: 2926–2932.

    CAS  Article  PubMed  Google Scholar 

  16. Kantarjian H, Sawyers C, Hochhaus A, Guilhot F, Schiffer C, Gambacorti-Passerini C et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 2002; 346: 645–652.

    CAS  Article  PubMed  Google Scholar 

  17. Kantarjian HM, Cortes J, O’Brien S, Giles FJ, Albitar M, Rios MB et al. Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase. Blood 2002; 99: 3547–3553.

    CAS  Article  PubMed  Google Scholar 

  18. Kantarjian HM, O’Brien S, Cortes JE, Smith TL, Rios MB, Shan J et al. Treatment of Philadelphia chromosome-positive, accelerated-phase chronic myelogenous leukemia with imatinib mesylate. Clin Cancer Res 2002; 8: 2167–2176.

    CAS  PubMed  Google Scholar 

  19. Kantarjian HM, Talpaz M, O’Brien S, Smith TL, Giles FJ, Faderl S et al. Imatinib mesylate for Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon-alpha: follow-up results. Clin Cancer Res 2002; 8: 2177–2187.

    CAS  PubMed  Google Scholar 

  20. Kantarjian HM, Smith T, O’Brien S, Beran M, Pierce S, Talpaz M et al. Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-therapy. Ann Int Med 1995; 122: 254–261.

    CAS  Article  PubMed  Google Scholar 

  21. Snedecor G, Cochran W . Statistical Methods. 7th edn. Iowa State University Press, Ames, Iowa, 1980.

    Google Scholar 

  22. Agresti A . Categorical Data Analysis. 2nd edn. John Wiley & Sons Inc. Hoboken, NJ, 1990.

    Google Scholar 

  23. Kaplan EL, Maier P . Non-parametric estimation from incomplete observations. J Am Stat Assoc 1965; 53: 457–481.

    Article  Google Scholar 

  24. Cox DR . Regression models and life tables. J R Stat Soc 1972; 34: 187–220.

    Google Scholar 

  25. Cortes J, Giles F, O’Brien S, Thomas D, Garcia-Manero G, Rios MB et al. Result of high-dose imatinib mesylate in patients with Philadelphia chromosome-positive chronic myeloid leukemia after failure of interferon-{alpha}. Blood 2003; 102: 83–86.

    CAS  Article  PubMed  Google Scholar 

  26. Kantarjian H, Talpaz M, O’Brien S, Garcia-Manero G, Verstovsek S, Giles F et al. High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. Blood 2004; 103: 2873–2878.

    CAS  Article  PubMed  Google Scholar 

  27. Soverini S, Martinelli G, Rosti G, Bassi S, Amabile M, Poerio A et al. ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the gimema working party on chronic myeloid leukemia. J Clin Oncol 2005, JCO.2005.2005.2531.

  28. Shah NP, Nicoll JM, Nagar B, Gorre ME, Paquette RL, Kuriyan J et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2002; 2: 117–125.

    CAS  Article  PubMed  Google Scholar 

  29. Willis S, Lange T, Demehri S, Otto S, Crossman L, Niederwieser D et al. High sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy. Blood 2005, 2005-2003-1036.

  30. Jabbour E, Cortes J, Kantarjian HM, Giralt S, Jones D, Jones R et al. Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after BCR-ABL kinase mutation-related imatinib failure. Blood 2006 [E-pub ahead of print (April 6, 2006)].

  31. Roche-Lestienne C, Lai JL, Darre S, Facon T, Preudhomme C . A mutation conferring resistance to imatinib at the time of diagnosis of chronic myelogenous leukemia. N Engl J Med 2003; 348: 2265–2266.

    Article  PubMed  Google Scholar 

  32. O’Hare T, Walters DK, Stoffregen EP, Jia T, Manley PW, Mestan J et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 2005; 65: 4500–4505.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to J Cortes.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Jabbour, E., Kantarjian, H., Jones, D. et al. Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate. Leukemia 20, 1767–1773 (2006). https://doi.org/10.1038/sj.leu.2404318

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2404318

Keywords

  • chronic myeloid leukemia
  • imatinib mesylate
  • mutations
  • P-loop

Further reading

Search

Quick links